Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts

被引:3
作者
Seitz, Christian Martin [1 ]
Eyrich, Matthias [2 ]
Greil, Johann [3 ]
Schlegel, Patrick [1 ]
Feuchtinger, Tobias [4 ]
Bader, Peter [5 ]
Ebinger, Martin [1 ]
Schwarze, Carl Philipp [1 ]
Schlegel, Paul Gerhardt [2 ]
Schumm, Michael [1 ]
Handgretinger, Rupert [1 ]
Lang, Peter [1 ]
机构
[1] Univ Childrens Hosp, Dept Gen Pediat, Hematol Oncol, D-72076 Tubingen, Germany
[2] Univ Childrens Hosp, Dept Hematol Oncol & Stem Cell Transplantat, D-97080 Wurzburg, Germany
[3] Univ Childrens Hosp, Dept Hematol Oncol, D-69120 Heidelberg, Germany
[4] Dr von Haunersches Kinderspital, Dept Hematol Oncol & Stem Cell Transplantat, D-80337 Munich, Germany
[5] Univ Childrens Hosp, Div Stem Cell Transplantat & Immunol, D-60590 Frankfurt, Germany
关键词
VERSUS-HOST-DISEASE; BLOOD STEM-CELLS; MATCHED UNRELATED DONORS; CD34(+) PROGENITOR CELLS; LONG-TERM SURVIVAL; PERIPHERAL-BLOOD; BONE-MARROW; ALLOGENEIC TRANSPLANTATION; ACUTE-LEUKEMIA; RECONSTITUTION;
D O I
10.1038/s41409-018-0212-7
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Transplantation of peripheral blood stem cells (PBSC) from matched unrelated donors (MUD) is still associated with a significant risk for graft vs. host disease (GvHD), especially in pediatric patients receiving grafts from adult donors containing high amounts of T cells. Here, we present long-term follow-up results on 25 pediatric patients, (acute leukemia n = 15, NHL n = 3, CML n = 3, MDS n = 5), transplanted with CD34 or CD133 positively selected PBSC from MUDs supplemented with an add-back of 1 x 10(7)*/kg body weight (kgBW) unselected T cells resulting in a median T-cell depletion (TCD) of 1.97 log. A total of 24*/25 (96%) patients had primary engraftment. Early T-cell recovery was significantly improved compared to patients receiving CD34-selected grafts without T-cell add-back and similar to patients receiving unmanipulated bone marrow. GvHD incidence was low with 8*/4% aGvHD grade II*/III, no grade IV and 13% limited cGvHD. In total, 16*/25 (64%) patients are alive after a median follow-up of 10 years. Five-year event-free survival (EFS) was 68%, relapse probability 24% and transplantation-related mortality (TRM) 12%. Thus, in PBSC allotransplants from MUD, partial TCD with serotherapy and CSA*/MTX prophylaxis, can effectively reduce GvHD without hampering engraftment and immune reconstitution.
引用
收藏
页码:53 / 62
页数:10
相关论文
共 35 条
[1]   Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors [J].
Anasetti, Claudio ;
Logan, Brent R. ;
Lee, Stephanie J. ;
Waller, Edmund K. ;
Weisdorf, Daniel J. ;
Wingard, John R. ;
Cutler, Corey S. ;
Westervelt, Peter ;
Woolfrey, Ann ;
Couban, Stephen ;
Ehninger, Gerhard ;
Johnston, Laura ;
Maziarz, Richard T. ;
Pulsipher, Michael A. ;
Porter, David L. ;
Mineishi, Shin ;
McCarty, John M. ;
Khan, Shakila P. ;
Anderlini, Paolo ;
Bensinger, William I. ;
Leitman, Susan F. ;
Rowley, Scott D. ;
Bredeson, Christopher ;
Carter, Shelly L. ;
Horowitz, Mary M. ;
Confer, Dennis L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (16) :1487-1496
[2]   Graft dysfunction and delayed immune reconstitution following haploidentical peripheral blood hematopoietic stem cell transplantation [J].
Ball, LM ;
Lankester, AC ;
Bredius, RGM ;
Fibbe, WE ;
van Tol, MJD ;
Egeler, RM .
BONE MARROW TRANSPLANTATION, 2005, 35 (Suppl 1) :S35-S38
[3]   Molecules and mechanisms of the graft-versus-leukaemia effect [J].
Bleakley, M ;
Riddell, SR .
NATURE REVIEWS CANCER, 2004, 4 (05) :371-380
[4]   Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts [J].
Bleakley, Marie ;
Heimfeld, Shelly ;
Loeb, Keith R. ;
Jones, Lori A. ;
Chaney, Colette ;
Seropian, Stuart ;
Cooley, Ted A. ;
Sommermeyer, Franziska ;
Riddell, Stanley R. ;
Shlomchik, Warren D. .
JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (07) :2677-2689
[5]   Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+selection and CD3+addback for pediatric patients with leukemias [J].
Bunin, N ;
Aplenc, R ;
Grupp, S ;
Pierson, G ;
Monos, D .
BONE MARROW TRANSPLANTATION, 2006, 37 (02) :143-149
[6]   Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning [J].
Chen, G. L. ;
Zhang, Y. ;
Hahn, T. ;
Abrams, S. ;
Ross, M. ;
Liu, H. ;
McCarthy, P. L. .
BONE MARROW TRANSPLANTATION, 2014, 49 (02) :248-253
[7]   A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors [J].
Eyrich, M ;
Leiler, C ;
Lang, P ;
Schilbach, K ;
Schumm, M ;
Bader, P ;
Greil, J ;
Klingebiel, T ;
Handgretinger, R ;
Niethammer, D ;
Schlegel, PG .
BONE MARROW TRANSPLANTATION, 2003, 32 (04) :379-390
[8]   T cell depletion utilizing CD34+ stem cell selection and CD3+ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients [J].
Geyer, Mark B. ;
Ricci, Angela M. ;
Jacobson, Judith S. ;
Majzner, Robbie ;
Duffy, Deirdre ;
Van de Ven, Carmella ;
Ayello, Janet ;
Bhatia, Monica ;
Garvin, James H., Jr. ;
George, Diane ;
Satwani, Prakash ;
Harrison, Lauren ;
Morris, Erin ;
Semidei-Pomales, Mildred ;
Schwartz, Joseph ;
Alobeid, Bachir ;
Baxter-Lowe, Lee Ann ;
Cairo, Mitchell S. .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (02) :205-219
[9]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
[10]  
2-F